Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
J Dermatolog Treat
; 32(5): 507-513, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-31647347
ABSTRACT
BACKGROUND:
Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.OBJECTIVE:
To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort.METHODS:
Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI).RESULTS:
A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect.CONCLUSIONS:
Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Prurito
/
Calidad de Vida
/
Dermatitis Atópica
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Dermatolog Treat
Asunto de la revista:
DERMATOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Italia